<code id='271DF76C66'></code><style id='271DF76C66'></style>
    • <acronym id='271DF76C66'></acronym>
      <center id='271DF76C66'><center id='271DF76C66'><tfoot id='271DF76C66'></tfoot></center><abbr id='271DF76C66'><dir id='271DF76C66'><tfoot id='271DF76C66'></tfoot><noframes id='271DF76C66'>

    • <optgroup id='271DF76C66'><strike id='271DF76C66'><sup id='271DF76C66'></sup></strike><code id='271DF76C66'></code></optgroup>
        1. <b id='271DF76C66'><label id='271DF76C66'><select id='271DF76C66'><dt id='271DF76C66'><span id='271DF76C66'></span></dt></select></label></b><u id='271DF76C66'></u>
          <i id='271DF76C66'><strike id='271DF76C66'><tt id='271DF76C66'><pre id='271DF76C66'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:8474
          David Liu- Broad Retreat
          David Liu proposed prime editing of genes in 2019. The technology has passed a big test. Courtesy ErikJacobs/Broad Institute

          Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called prime editing to edit liver cells in monkeys.

          The results, presented at the European Society of Gene & Cell Therapy meeting in Brussels, are a major step for a technology that could transform treatment of numerous diseases.

          advertisement

          “I think the big celebration here is we’re showing, in primates, for the company, that we have a delivery system that is working and is safe,” said Jeremy Duffield, Prime’s chief scientific officer.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more
          Acelyrin, a rare IPO success, stumbles in its first big test
          Acelyrin, a rare IPO success, stumbles in its first big test

          MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          White House touts steps to stem shortages of cancer treatments

          TheWhiteHouseoutlineditseffortstoendshortagesofthreekeygenericchemotherapies.Butexpertswantmoremored